

James A Watson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/250569/publications.pdf>

Version: 2024-02-01

53
papers

2,006
citations

471509

17
h-index

289244

40
g-index

74
all docs

74
docs citations

74
times ranked

4855
citing authors

#	ARTICLE	IF	CITATIONS
1	Methaemoglobinaemia and the radical curative efficacy of 8-aminquinoline antimalarials. British Journal of Clinical Pharmacology, 2022, 88, 2657-2664.	2.4	5
2	Severe malaria, Pascalian therapeutics and the US FDA. Clinical Infectious Diseases, 2022, , .	5.8	0
3	Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2022, 112, 824-835.	4.7	3
4	Characterizing SARS-CoV-2 Viral Clearance Kinetics to Improve the Design of Antiviral Pharmacometric Studies. Antimicrobial Agents and Chemotherapy, 2022, 66, .	3.2	16
5	Stopping prereferral rectal artesunate " a grave error. BMJ Global Health, 2022, 7, e010006.	4.7	11
6	A semi-supervised learning framework for quantitative structure-activity regression modelling. Bioinformatics, 2021, 37, 342-350.	4.1	5
7	Prediction of disease severity in young children presenting with acute febrile illness in resource-limited settings: a protocol for a prospective observational study. BMJ Open, 2021, 11, e045826.	1.9	12
8	Time-to-death is a potential confounder in observational studies of blood transfusion in severe malaria. Lancet Haematology,the, 2021, 8, e12.	4.6	1
9	Protective effect of Mediterranean-type glucose-6-phosphate dehydrogenase deficiency against Plasmodium vivax malaria. ELife, 2021, 10, .	6.0	22
10	The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions. Wellcome Open Research, 2021, 6, 71.	1.8	5
11	Tafenoquine for the prevention of Plasmodium vivax malaria relapse. Lancet Microbe, The, 2021, 2, e175-e176.	7.3	13
12	Improving statistical power in severe malaria genetic association studies by augmenting phenotypic precision. ELife, 2021, 10, .	6.0	22
13	Determinants of Primaquine and Carboxyprimaquine Exposures in Children and Adults with Plasmodium vivax Malaria. Antimicrobial Agents and Chemotherapy, 2021, 65, e0130221.	3.2	10
14	The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions. Wellcome Open Research, 2021, 6, 71.	1.8	4
15	Questioning the Claimed Superiority of Malaria Parasite Ex Vivo Viability Reduction Over Observed Parasite Clearance Rate?. Journal of Infectious Diseases, 2021, 224, 738-739.	4.0	0
16	Falciparum malaria mortality in sub-Saharan Africa in the pretreatment era. Trends in Parasitology, 2021, , .	3.3	1
17	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine, 2020, 383, 2030-2040.	27.0	1,013
18	COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. PLoS Medicine, 2020, 17, e1003252.	8.4	86

#	ARTICLE	IF	CITATIONS
19	Graphing and reporting heterogeneous treatment effects through reference classes. <i>Trials</i> , 2020, 21, 386.	1.6	3
20	Non-adherence in non-inferiority trials: pitfalls and recommendations. <i>BMJ, The</i> , 2020, 370, m2215.	6.0	29
21	Concomitant Bacteremia in Adults With Severe Falciparum Malaria. <i>Clinical Infectious Diseases</i> , 2020, 71, e465-e470.	5.8	22
22	Machine learning analysis plans for randomised controlled trials: detecting treatment effect heterogeneity with strict control of type I error. <i>Trials</i> , 2020, 21, 156.	1.6	11
23	A molecular barcode to inform the geographical origin and transmission dynamics of <i>Plasmodium vivax</i> malaria. <i>PLoS Genetics</i> , 2020, 16, e1008576.	3.5	24
24	A cautionary note on the use of unsupervised machine learning algorithms to characterise malaria parasite population structure from genetic distance matrices. <i>PLoS Genetics</i> , 2020, 16, e1009037.	3.5	5
25	A Bayesian phase 2 model based adaptive design to optimise antivenom dosing: Application to a dose-finding trial for a novel Russell's viper antivenom in Myanmar. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008109.	3.0	4
26	Estimating the Proportion of <i>Plasmodium vivax</i> Recurrences Caused by Relapse: A Systematic Review and Meta-Analysis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 1094-1099.	1.4	77
27	Concentration-dependent mortality of chloroquine in overdose. <i>ELife</i> , 2020, 9, .	6.0	21
28	Title is missing!. , 2020, 16, e1009037.		0
29	Title is missing!. , 2020, 16, e1009037.		0
30	Title is missing!. , 2020, 16, e1009037.		0
31	Title is missing!. , 2020, 16, e1009037.		0
32	Title is missing!. , 2020, 14, e0008109.		0
33	Title is missing!. , 2020, 14, e0008109.		0
34	Title is missing!. , 2020, 14, e0008109.		0
35	Title is missing!. , 2020, 14, e0008109.		0
36	The haematological consequences of <i>Plasmodium vivax</i> malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. <i>BMC Medicine</i> , 2019, 17, 151.	5.5	34

#	ARTICLE	IF	CITATIONS
37	Investigating causal pathways in severe falciparum malaria: A pooled retrospective analysis of clinical studies. <i>PLoS Medicine</i> , 2019, 16, e1002858.	8.4	26
38	Pharmacokinetic-Pharmacodynamic Assessment of the Hepatic and Bone Marrow Toxicities of the New Trypanoside Fexinidazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	17
39	A decision-theoretic approach to the evaluation of machine learning algorithms in computational drug discovery. <i>Bioinformatics</i> , 2019, 35, 4656-4663.	4.1	15
40	The probability of a sequential <i>Plasmodium vivax</i> infection following asymptomatic <i>Plasmodium falciparum</i> and <i>P. vivax</i> infections in Myanmar, Vietnam, Cambodia, and Laos. <i>Malaria Journal</i> , 2019, 18, 449.	2.3	7
41	Resolving the cause of recurrent <i>Plasmodium vivax</i> malaria probabilistically. <i>Nature Communications</i> , 2019, 10, 5595.	12.8	70
42	Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in <i>Plasmodium vivax</i> Malaria. <i>Clinical Infectious Diseases</i> , 2019, 68, 1311-1319.	5.8	49
43	Collider bias and the apparent protective effect of glucose-6-phosphate dehydrogenase deficiency on cerebral malaria. <i>ELife</i> , 2019, 8, .	6.0	15
44	Characterizing Blood-Stage Antimalarial Drug MIC Values <i>In Vivo</i> Using Reinfection Patterns. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	12
45	Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006440.	3.0	45
46	Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in <i>Plasmodium vivax</i> Malaria. <i>Clinical Infectious Diseases</i> , 2018, 67, 1543-1549.	5.8	52
47	Age, exposure and immunity. <i>ELife</i> , 2018, 7, .	6.0	20
48	Split dosing of artemisinins does not improve antimalarial therapeutic efficacy. <i>Scientific Reports</i> , 2017, 7, 12132.	3.3	16
49	Antimalarial Resistance Unlikely To Explain U.K. Artemether-Lumefantrine Failures. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	1
50	Characterizing variation of nonparametric random probability measures using the Kullback-Leibler divergence. <i>Statistics</i> , 2017, 51, 558-571.	0.6	5
51	Modelling primaquine-induced haemolysis in G6PD deficiency. <i>ELife</i> , 2017, 6, .	6.0	38
52	Rejoinder: Approximate Models and Robust Decisions. <i>Statistical Science</i> , 2016, 31, .	2.8	4
53	Approximate Models and Robust Decisions. <i>Statistical Science</i> , 2016, 31, .	2.8	27